This Hainan pharmaceutical company’s new coronavirus infection treatment drug was approved for marketing
Read Time:48 Second
On January 29, according to the official website of the State Drug Administration, the State Drug Administration, in accordance with the relevant provisions of the Drug Administration Law, conducted emergency review and approval in accordance with the special drug approval procedures, and conditionally approved the Class 1 innovative drug centronavir tablets/ritonavir tablets combination package (trade name: Centronoxin) declared by Hainan Centron Pharmaceutical Co. Ltd. declared a Class 1 innovative drug hydrobromide rimivir tablets (trade name: Mindvir) to market.
Both of these drugs are oral small molecules for the treatment of mild to moderate novel coronavirus infection (COVID-19) in adult patients. Patients should use the drugs strictly according to the instructions under the guidance of a physician.
The State Drug Administration requires the holder of the marketing license to continue the relevant research work, complete the requirements of the attached conditions by the deadline, and submit the results of the follow-up study in a timely manner.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating